TLOG.
The IAP class of drug has an issue with liver enzymes at therapeutic doses. Maybe just a really simplistic way of looking at this, but personally, I dont know how it would be successful given HBV is already compromising the liver, and the drug itself is likely to further enhance a bad effect on the liver. Perhaps you dont need as high a dose in HBV as you would in solid tumors ( which has the elevated liver tox issues), thereby, not coming across associated liver tox, but i havent really looked.
Again...just my general off the cuff first thought observations. I am sure someone much smarter here could opine more about it.
